Lymphatic Malformations clinical trials at UCSF
2 research studies open to eligible people
Lymphatic malformations are growths that form in the lymphatic system due to genetic changes. UCSF is testing a drug called RLY-2608 to see its effects on people with PIK3CA mutations. Another study is examining the impact of Alpelisib on similar malformations.
Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
open to eligible people ages 2 years and up
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
San Francisco, California and other locations
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
open to eligible people ages 0-100
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
Oakland, California and other locations
Last updated: